MANKIND PHARMA: APPROVES MERGER OF TWO WHOLLY OWNED SUBSIDIARIES; PLANS INTERNAL BUSINESS RESTRUCTURING

• Merger Approval: Board approved amalgamation of Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma • Effective Date: April 1, 2027, proposed as the appointed date for the merger • Corporate Simplification: Merger aims to streamline group structure, consolidate operations and reduce the number of legal entities • Cost Efficiency: Expected to reduce administrative, operational and regulatory compliance costs • Resource Optimisation: Consolidation aims to improve resource utilisation, operational efficiency and management oversight • Consumer Business Restructuring: Board also took note of the proposed merger of Upakarma Ayurveda into Mankind Consumer Products, both wholly owned within the group • Consumer Growth: Restructuring expected to support faster product launches, portfolio expansion and cross-selling opportunities in OTC healthcare and wellness products • Shareholding Impact: No fresh equity shares or cash consideration involved; Mankind Pharma's shareholding structure remains unchanged • Regulatory Approvals: Proposed mergers remain subject to necessary statutory, regulatory and NCLT approvals

MANKIND PHARMA LIMITED

← Back to feed